OREMAVEN
XMM 7,722.00 -2.63% YTD +5.6% OM ASX 450.55 -2.56% YTD +0.1% OM PRECIOUS 349.20 -2.24% YTD +2.5% OM EX-PREC 418.91 -2.72% YTD -1.1% XAU 4,115.59 +2.31% YTD -4.9% GLD 375.49 +0.81% YTD -5.2% GDX 85.75 +1.37% YTD -0.0% SIL 77.33 -1.00% YTD -7.3% COPX 70.23 -5.81% YTD -1.8% URNM 40.07 -2.79% YTD -27.0%
2026-11-06

← CYL management

Full background report

James Champion de Crespigny

Managing Director and Chief Executive Officer

Career chronology

Contributions and company outcomes

FY2026 output reached guidance

FY2026 · issuer reported · medium materiality

Catalyst reports 103,761 ounces produced from the Plutonic Gold Belt in FY2026, within its 100,000–110,000 ounce original guidance.

Attribution: Role overlaps event; causation unproven. The CEO led the company during the period; the result is a team outcome and his individual contribution is not isolated.

Relevance: Evidence of delivery during the team’s tenure.

Annual Report to shareholders 2026 (PDF p.6, chair and CEO letter)

Business failures and setbacks

Trident and Old Highway production deferred

September 2026 · issuer reported · medium materiality

Catalyst’s September quarterly deferred Trident and Old Highway production from FY2027 to FY2028. It cited permitting timelines, updates to estimates and Trident development running behind its anticipated schedule.

Attribution: Role overlaps event; causation unproven. The CEO led the company during the delay; individual causation has not been established.

Relevance: Execution timing is relevant to the team’s delivery record.

September 2026 Quarterly Activities Report (PDF pp.1 and 3, FY27 guidance and Trident development)

Industrial safety

Injury frequency rose, then improved in September

FY2026 to September 2026 · issuer reported · medium materiality

The issuer reports twelve-month TRIFR increased from 6.3 at 30 June 2025 to 10.4 at 30 June 2026; its September quarterly says it subsequently fell from ten to seven. The board reported a zero score for the safety and training team incentive measure.

Attribution: Role overlaps event; causation unproven. The CEO held the role during the reporting period; the company-level measure does not establish personal fault.

Relevance: A material safety trend and company response.

Annual Report to shareholders 2026 (PDF pp.10 and 35, safety and remuneration team scorecard); September 2026 Quarterly Activities Report (PDF p.1, quarterly safety highlights)

Governance and interests

Court granted corporate disclosure relief

August 2025 · documented · medium materiality

In August 2025 the Federal Court granted Catalyst remedial orders concerning its FY2024 consolidated entity disclosure statement and the validity of certain cleansing notices. Catalyst described the underlying misstatement as minor and technical.

Attribution: Role overlaps event; causation unproven. The CEO held office, but the orders reviewed do not establish individual fault; the source’s characterisation is the company’s.

Relevance: Shows a corporate reporting and remediation issue.

Court orders confirmed (pp.1–3, company announcement and Federal Court orders)

Suitability for the current role

Disclosed role and relevant experience

Before and during Catalyst role · analyst inference · medium materiality

Catalyst reports he is a chartered accountant with prior director roles at mining advisor Cutfield Freeman & Co and associate director role at EMR Capital; exact dates and independent qualifications were not verified.

Attribution: Responsibility not applicable. Role relevance is an analytical inference from the cited disclosures; it is not independent credential verification or a demonstrated personal performance assessment.

Relevance: Helps assess role relevance, subject to evidence limits.

Annual Report to shareholders 2026 (PDF p.18, directors’ biography)

Evidence gaps

  • Separate person-specific searches for each topic, comprehensive employer histories, court and regulator checks, and independent qualification verification remain incomplete.

  • No assertion of criminal or regulatory clearance follows from this limited public-source screening.